Company: MIRM
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001759425-25-000032
Chunk: 335

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 335
---
Operating lease liabilities(408)(269)Net cash (used in) provided by operating activities(1,961)15,212 Investing activitiesPurchase of investments(33,526)— Proceeds from maturities of investments17,433 — Purchase of property and equipment(41)(13)Net cash used in investing activities(16,134)(13)Financing activitiesProceeds from issuance of common stock pursuant to equity plans6,359 1,205 Net cash provided by financing activities6,359 1,205 Effect of exchange rate on cash, cash equivalents and restricted cash1,055 113 Net (decrease) increase in cash, cash equivalents and restricted cash(10,681)16,517 Cash, cash equivalents and restricted cash at beginning of period222,928 286,326 Cash, cash equivalents and restricted cash at end of period$212,247 $302,843  Supplemental disclosure of cash flow information:Operating cash flows paid for operating lease$583 $289 Cash paid for income taxes$162 $139 Non-cash operating, investing and financing activities:Accrued milestone payments classified as intangible assets, net$— $10,000 Decrease in ROU assets and lease liabilities due to lease modification$649 $723 Stock-based compensation capitalized to inventory$212 $214 Conversion of convertible notes, net into shares of common stock$6 $— 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

Mirum Pharmaceuticals, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

(Unaudited)

1. Organization and Description of Business

Mirum Pharmaceuticals, Inc. (the “Company”) was incorporated in the State of Delaware on May 2, 2018, and is headquartered in Foster City, California. The Company is a biopharmaceutical company dedicated to transforming the treatment of rare diseases.The Company has three approved medicines: LIVMARLI® (maralixibat) (“Livmarli”), Cholbam® (cholic acid) capsules (“Cholbam”), and Chenodal® or CTEXLI® (chenodiol) tablets (“Chenodal” or “Ctexli”). Livmarli is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (“ALGS”) in the United States (“U.S.”), the European Union (“